Psoriasis

MILAN — A basket study of a new topical phosphodiesterase 4 inhibitor demonstrated efficacy superior to that of placebo in mild to moderate plaque psoriasis.

Bristol Myers Squibb’s deucravacitinib was approved by the FDA for the treatment of moderate to severe plaque psoriasis, the company announced in a press release.

MILAN — Pediatric patients experienced improved psoriasis symptoms and quality of life with ixekizumab treatment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.

Gradient-boosted decision trees and logistic regression were effective in identifying the optimal biologic therapy for psoriasis patients, according to a study.

Psoriasis patients reported a desire for cheaper oral and topical medications and further research into non-pharmacotherapeutic options to treat their condition, according to findings from a study.

Interleukin-17 inhibition with brodalumab was associated with a rapid onset of action compared with other biologics in patients with moderate to severe psoriasis, according to a study.

For patients with psoriasis, tools such as the Psoriasis Epidemiology Screening Tool can help predict the possibility of future psoriatic arthritis development, according to a study.

Janus kinase, or JAK, inhibitors have been used in the treatment of rheumatological disorders, including psoriatic arthritis. Their benefit in psoriatic skin disease is still being studied, however some safety concerns have kept the class of drugs as a second-line treatment option.

In this issue of Healio Psoriatic Disease, we focus on JAK inhibitors.

Union Therapeutics has completed patient enrollment in a phase 2b trial of orismilast MR tablets for the treatment of psoriasis, the company announced in a press release.